Review Article Transcutaneous electrical acupoint stimulation for rehabilitation after total knee arthroplasty: a systematic review and meta-analysis

Le Zhang^{1*}, Ziming Zhang^{1*}, Zehua Chen^{2*}, Guixin Zhang³, Tiantian Zhang¹, Haoming Kuang¹, Zhifei Peng¹, Kuan Rong⁴, Liang Ou⁴, Jianjun Kuang^{4,5}

¹Hunan University of Chinese Medicine, Changsha 410208, Hunan, China; ²Department of Orthopedics, Orthopedics Hospital of Chinese Medicine Zhuzhou City, Zhuzhou 412007, Hunan, China; ³Department of Geriatric Orthopeadics, Shenzhen Pingle Orthopedic Hospital, Shenzhen 518000, Guangdong, China; ⁴Hunan Academy of Chinese Medicine, Changsha 410013, Hunan, China; ⁵Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine, Changsha 410013, Hunan, China: ^{*}Equal contributors and co-first authors.

Received January 8, 2024; Accepted April 17, 2024; Epub May 15, 2024; Published May 30, 2024

Abstract: Background: Rehabilitation after total knee arthroplasty (TKA) has become an indispensable part of the treatment strategy for degenerative joint disease. Despite some current research demonstrating efficacy of transcutaneous electrical acupoint stimulation (TEAS) for post-TKA rehabilitation, the evidence is not conclusive. Objective: To systematically assess the evidence supporting TEAS for rehabilitation after TKA. Methods: A literature search of the PubMed, Embase, The Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature Database, Wanfang, and Chinese Scientific Journal Data databases for relevant studies published up to October 16, 2023, was performed. Main indicators included visual analog scale (VAS) and functional scores; secondary indicators included range of motion (ROM), interleukin-6 (IL-6) and C-reactive protein (CRP) levels, and analgesiarelated adverse events. Risk of bias was evaluated using the Cochrane Tool, and meta-analysis was performed using Review Manager version 5.4. Results: Twenty RCTs with 1295 participants were included. TEAS improved several outcomes compared to control groups. The TEAS group had significantly greater pain reduction at postoperative 6 h, 12 h, 24 h, 48 h, 72 h, 7 days, and 14 days. Moreover, TEAS significantly improved the Hospital for Special Surgery Knee Score, Knee Society Score, and ROM. Patients who underwent TEAS exhibited a lower incidence of analgesiarelated adverse events and lower IL-6 and CRP levels. Conclusions: Available evidence indicates that the application of TEAS in patients undergoing TKA is related to postoperative pain alleviation, functional improvement, and fewer adverse events associated with analgesia.

Keywords: Transcutaneous electrical acupoint stimulation, total knee arthroplasty, rehabilitation, post-operative pain, function, systematic review

Introduction

Knee osteoarthritis (KOA) is a prevalent degenerative joint illness in middle-aged and elderly patients, characterized by joint pain, swelling, and mobility impairment [1]. As KOA worsens, the cartilage destruction leads to loss of joint function, which seriously affects people's quality of life [2]. Total knee arthroplasty (TKA) is regarded as the optimum therapy for severe KOA, and is widely used to recover function and alleviate pain in the patients with advanced KOA [3]. Nonetheless, there are some complications after TKA, for instance post-operative pain, functional limitation, and analgesia-related side effects, which, to some extent, significantly affect postoperative rehabilitation [4]. As previously reported, postoperative pain is the main hurdle to recovery of motion and return to activity after TKA [5].

Currently, post-operative pain relief is a crucial aspect of rehabilitation, which can be achieved by using pharmacologic interventions, including nonsteroidal anti-inflammatory drugs [6], opioids [7], and steroids [8]. However, the adverse reactions caused by drugs includingnausea, vomiting, respiratory depression and addiction are frequently reported, which limit clinical application [9, 10]. Therefore, many alternative therapies have been developed, including sports therapy [11], acupuncture [12], transcutaneous electrical nerve stimulation (TENS) [13], and transcutaneous electrical acupoint stimulation (TEAS) [14], in order to complement or replace conventional pharmacological interventions.

As a non-invasive treatment, TEAS achieves its therapeutic effect by placing electrodes - rather than needles - on the surface of the skin where acupuncture points are located [15]. TEAS combines the benefits of traditional Chinese acupuncture and TENS, which is widely accepted and applied worldwide [16, 17]. In recent vears, studies have provided evidence supporting many positive benefits of TEAS, including improved postoperative cognitive function, alleviation of pain, and promotion of recovery after surgery [18-20]. In view of this, we evaluated the influence of TEAS for rehabilitation after TKA by analyzing all presently available randomized controlled trials (RCTs). This study evaluated the effectiveness of TEAS for rehabilitation after TKA using various indicators including a visual analog scale (VAS), Hospital for Special Surgery Knee Score (HSS), Knee Society Score (KSS), range of motion (ROM) of the knee, C-reactive protein (CRP), and interleukin-6 (IL-6). Our study aims to provide effective and reliable treatment recommendations for postoperative rehabilitation of TKA.

Methods

This study was performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (i.e., "PRISMA") guidelines [21]. This systematic review was registered with the International Prospective Register of Systematic Reviews (i.e., "PROSPERO") under accession ID number CRD42023424323 (https://www.crd.york.ac. uk/PROSPERO/display_record.php?RecordID= 424323).

Research strategy

A literature search of the PubMed, Embase, Cochrane Central Register of Controlled Trials (Central), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Data (VIP), and Wanfang databases was performed for potentially eligible trials published up to October 16, 2023. The search strategy used medical subject heading (MeSH) terms combined with free text, including: "transcutaneous electrical acupoint stimulation", "TEAS", "TAES", "total knee replacement", "knee replacement arthroplasty", "total knee replacement", "TKA", and "placebo". Detailed search strategies are presented in <u>Supplementary</u> <u>Table 1</u>.

Eligibility criteria

RCTs investigating the use of TEAS for rehabilitation after TKA were retrieved. The inclusion criteria were as follows: Patients, individuals undergoing primary TKA for KOA; Intervention, TEAS alone or in combination with other treatments; Comparator(s), sham intervention, other treatments, or no therapy; Outcomes, visual analog scale (VAS) and functional scores as the primary outcomes and secondary outcomes including ROM, C-reactive protein (CRP), interleukin-6 (IL-6), and nausea/vomiting (adverse reactions associated with analgesia); and Study design, RCTs. Studies including experimental and/or control groups that included other interventional therapies with Chinese medicine (e.g., Chinese herbal medicine and electrical acupuncture) and those that did not report the primary outcomes were excluded. In addition, protocols, reviews, animal studies, duplicate studies, and those with unavailable full-text or complete data were also excluded.

Data extraction

Using a pre-designed data extraction form (spreadsheet), 2 investigators (LZ and ZMZ) independently extracted essential content from the included studies: lead author; year of publication; patient age and gender; type of intervention; intervention parameters; acupoints; stimulation frequency; and outcomes, among others. Any discrepancies in the cross-checking procedure were resolved through a consensus discussion or, otherwise, arbitrated by a third researcher (ZHC).

Quality assessment

In accordance with the standards recommended in the Cochrane manual [22], the methodologic quality of all included literature was evalu-



ated independently by two reviewers (LZ and ZMZ). Discussion with the third author (ZHC) resolved any discrepancies. Risk of bias for each trial was assessed from seven perspectives: sequence generation, allocation concealment, participant and personnel blinding, outcome assessment blinding, incomplete outcome data, selective reporting, and other bias. There are three levels of risk: high, low, or unclear, based on the evaluation result for each item.

Statistical analysis

The Review Manager 5.4 was applied to all meta-analyses of observational indicators in the selected literatures, and the corresponding results were intuitively displayed on the forest map. In this review, we used mean difference (MD) to pool continuous variables. If each original study outcome indicator unit is inconsistent, the standard mean difference (SMD) alternative MD should be selected. Dichotomous variables were pooled using the odds ratio (OR). All pooling effects are reported with 95% confidence intervals (95% CI). A P value of less than 0.05 was considered significant. The test for heterogeneity was performed using the 1^2 sta-

tistic and the Cochran Q testing. High heterogeneity was indicated by an I² statistic > 50%. Fixed effects model was used for I² statistic < 50%, otherwise random effects model was selected. If there was substantial heterogeneity, subgroup analysis was used to examine the sources of heterogeneity. Sensitivity analysis tested the stability of the results. Stata 14 (USA, Stata Corp LP, 2015) was used to estimate publication bias using Begg's and Egger's tests.

Results

Study selection

In total, the database search identified 526 relevant clinical trials. After eliminating 213 repeated studies and removing 293 papers by the prescreening, viewing abstracts,

and full articles, 20 RCTs [23-42] involving 1, 295 TKA patients were gualified to extract data. A flowchart of the selection process is shown in Figure 1, and the basic information of each included article is presented in Table 1. With the exception of one study [33] in South Korea, the remaining studies were conducted in China. In the present review, nineteen studies [23-32, 34-42] were written in Chinese, and only one study [33] was published in English. Of the 20 reported interventions, 15 trials [24, 26-29, 31, 32, 34-38, 40-42] were treated with 2~100 Hz, and two studies [23, 30] applied 5 or 100 Hz. Of 20 RCTs, the most commonly used acupoints were "Hegu" (LI4), "Neiguan" (PC6), and "Yinlingguan" (SP9), etc. Study evaluation time points ranged from 1 to 30 days after surgery.

Risk of bias

All included trials were reported as randomized. Of these, 13 studies [23, 24, 26, 28, 29, 32, 35-38, 40-42] were conducted with a random number table, 2 trials [31, 34] adopted randomized block design and 1 [33] was performed through the throw of dice. Two studies

Table 1. Characteristics of included randomized clinical trials

First author (year)	Age (years)	Gender (Male/ Female)		Sample size		Intervention	Intervention		
year)	EG	CG	EG	CG	EG	CG	EG	CG	Acupoints/Stimulation frequency/time	 (Time points for evaluation)
iang et al. 2017 [23]	65.90 ± 4.17	64.40 ± 4.14	11/29	9/31	40	40	TEAS, routine rehabili- tation	Routine rehabilita- tion	SP10, ST34, ST31, ST32/5 HZ/20 min, once daily, 2 days after surgery	KSS (on 28 d), HSS (on 28 d)
Vu et al. 2017 [24]	70.75 ± 8.23	70.55 ± 7.44	44/16	46/14	60	60	TEAS, routine rehabili- tation	Routine rehabilita- tion	SP9, GB34, SP10, ST36, ST33, ST34/2~100 HZ/30 min, once daily, 1 day after surgery	VAS (30 d), HSS (30 d)
3ai 2018 25]	66.75 ± 6.32	66.80 ± 7.35	3/17	3/17	20	20	TEAS, cocktail therapy	Cocktail therapy	SP10, SP9, GB34, ST36/NR/30 min, twice daily, 1 day after surgery	VAS (12, 24, 48, 72 h), ROM of knee (24, 48, 72 h), Analgesia- Related Adverse Effects (72 h)
Zhang et al. 2019 [26]	69.2 ± 3.0	68.6 ± 3.2	14/26	11/29	40	40	TEAS, analgesia pump	Sham TEAS, Analge- sia pump	LI4, PC6/2~100 HZ/30 min before anesthe- sia, through completion of surgery	VAS (1, 6, 24, 48 h), Analgesia- Related Adverse Effects (2 d)
Zhuang 2019 [27]	65.60 ± 6.34	66.90 ± 6.77	5/25	7/23	30	30	TEAS, routine rehabili- tation	Routine rehabilita- tion	SP9, GB34, SP10, ST36, ST40, BL60, GB39, SP6/2~100 HZ/30 min, once daily, 1 day after surgery	VAS (1, 3, 7 d), HSS (7 d)
Chen et al. 2019 [28]	65.92 ± 7.60	65.64 ± 7.15	5/20	4/21	25	25	TEAS, analgesia pump, routine reha- bilitation	Analgesia pump, rou- tine rehabilitation	PC6, LI4, SP10, ST34, SP9, ST36/2~100 HZ/30 min preoperative and 30 min before postoperative rehabilitation	VAS (1, 2, 3, 5, 7 d), ROM of kne (3, 5, 7 d), Analgesia-Related Adverse Effects (3 d)
Zhang(b) 2019 [29]	66.10 ± 6.03	67.48 ± 5.43	2/28	5/25	30	30	TEAS	Blank	LI4, PC6/2~100 HZ/30 min before anesthe- sia, through completion of surgery	VAS (1 d), Analgesia-Related Adverse Effects (1 d)
Li 2019 [30]	68.64 ± 5.74	69.12 ± 5.88	Ν	IR	25	25	TEAS, analgesia drugs, routine reha- bilitation	Analgesia drugs, rou- tine rehabilitation	SP9, GB34/100 HZ/30 min, once daily, 30 min before routine rehabilitation	KSS (7, 14 d), ROM of knee (3, 7, 14 d)
Wang 2019 [31]	64.60 ± 4.51	64.11 ± 4.92	13/7	12/8	20	20	TEAS, analgesia pump	Analgesia pump	LI4, PC6, ST36, GB31, BL57, SP6/2~100 HZ/15 min before anesthesia, and 30 min, once daily, 1 day after surgery	VAS (1, 2, 3, 4 d), Analgesia-Rela ed Adverse Effects (5 d), IL-6 (1, 5 d), CRP (1, 3, 5 d)
Tong 2020 [32]	68.7 ± 4.9	69.2 ± 7.6	5/15	1/19	20	20	TEAS, analgesia drugs	Analgesia drugs	LI4, PC6/2~100 HZ/30 min before anesthe- sia, through completion of surgery	VAS (1, 2, 6, 12, 24, 48 h), Analasia-Related Adverse Effects (2 d)
Kim et al. 2021 [33]	63.53 ± 4.29	62.07 ± 3.88	6/9	8/7	15	15	TEAS	TENS	BL36, BL37, ST32, ST34, SP10/2~150 HZ/30 min, 5 times per week, 1 day after surgery	VAS (14 d), CRP (1 d)
Wang(a) 2021 [34]	69.7 ± 4.31	70.87 ± 5.56	13/21	9/23	34	32	TEAS	Sham TEAS	GB20, Ll4, PC6/2~100 HZ/30 min before anesthesia, through completion of surgery	VAS (6, 12, 24, 48 h), Analgesia- Related Adverse Effects (2 d), IL- (6 h after surgery, 1 d)
Wang(b) 2021 [35]	65.94 ± 3.87	65.16 ± 2.68	11/20	6/25	31	31	TEAS, analgesia drugs	Analgesia drugs	LI4, PC6, SP6, GB39, ST36/2~100 HZ/30 min, 1 day before surgery	VAS (1, 2, 3, 5, 7 d)
.i 2021 36]	66.95 ± 3.46	66 ± 3.76	5/15	6/14	20	20	TEAS, analgesia pump, femoral nerve blocked	Analgesia pump, femoral nerve blocked	SP9, GB34, ST36, SP6, ST34, GB39, BL60/2~100 HZ/30 min, once daily, 2 days after surgery	VAS (2, 3, 5, 7 d), HSS (2, 3, 5, 7 d), Analgesia-Related Adverse Effects (7 d)
Hu et al. 2021 [37]	70,	~88	52,	/48	50	50	TEAS	Blank	SP12, ST31, ST36, SP6, SP10/2~100 HZ/30 min, 1 day before surgery and 30 min before anesthesia	VAS (1, 6, 24, 48 h), Analgesia- Related Adverse Effects (1 d), IL- (Immediately after surgery), CRF (Immediately after surgery)

Cui 2021 [38]	62.9 ± 5.05	64.20 ± 5.99	1/19	4/16	20	20	TEAS, analgesia pump, routine reha- bilitation	Analgesia pump, rou- tine rehabilitation	SP9, GB34, ST34, ST36, BL60, GB39, SP6/2~100 HZ/30 min, once daily, 30 min before routine rehabilitation	VAS (2, 3, 5, 7 d), HSS (2, 3, 5, 7 d), ROM of knee (2, 3, 5, 7 d), Analgesia-Related Adverse Effects (7 d)
Xie 2021 [39]	67.71 ± 5.41	65.22 ± 6.04	2/39	8/33	41	41	TEAS, routine rehabili- tation	Sham TEAS, routine rehabilitation	SP10, ST34, BL37, BL40/1~20 HZ/30 min, twice daily, 3 days after surgery	VAS (1, 2, 3, 7, 14 d), KSS (14, 30 d), ROM of knee (7, 14 d)
Zhang 2021 [40]	69.78 ± 4.63	70.89 ± 4.68	9/23	13/22	32	35	TEAS, analgesia drugs, routine reha- bilitation	Analgesia drugs, rou- tine rehabilitation	SP9, SP10, ST34, ST36/2~100 HZ/1 day before surgery	VAS (12, 24, 48 h), HSS (7, 14 d), ROM of knee (12, 24, 48 h)
Wang et al. 2022 [41]	60 [,]	~84	N	R	24	24	TEAS	Blank	LI4, PC6/2~100 HZ/30 min before anesthe- sia, through completion of surgery	VAS (1, 6, 24 h), Analgesia-Related Adverse Effects (1 d), IL-6 (1 d)
Bai et al. 2023 [42]	65.61 ± 5.73	65.07 ± 5.98	28/43	30/39	71	69	TEAS, analgesia drugs	Analgesia drugs	SP9, GB34, SP10, ST36, ST34, BL40/2~100 HZ/30 min, twice daily, 1 day after surgery	VAS (1, 3, 7 d), HSS (7, 14 d), Analgesia-Related Adverse Effects (7 d)



Figure 2. Risk of bias graph.

[25, 27] mentioned randomization with without specific methods. Three studies [26, 30, 39] described the correct method of complete allocation concealment, and the remaining trials were unclear for allocation concealment. Three studies [26, 30, 39] reported detailed participant blinding methods, and most included studies performed well on detection bias. All studies had a low risk of incomplete outcome data. It was difficult to assess selective reporting in this study because most research protocols were unavailable. The risk of bias assessments for the selected studies are summarized in **Figure 2**.

Meta-analysis

Post-operative pain: Meta-analysis results and evidence quality for the effect of TEAS on rehabilitation after TKA are shown in **Table 2**. A total of eighteen studies reported postoperative VAS, with 583 cases in the experimental group (EG) and 576 cases in the control group (CG) overall. An overall meta-analysis indicated that the EG had considerably improved VAS [MD = -0.60 (95% CI: -0.74, -0.47), P < 0.00001, I^2 = 84%] when compared to the CG, with substantial heterogeneity, using a random-effects model. To identify sources of high heterogeneity,

Variable	No. of Studies	No. of Participants	Effect Estimate (95% CI)	I ² Heterogeneity, %	GRADE
Post-operative Pain			,		
6 h	5	336	-0.86 (-1.35 to -0.37)	91	Very Low
12 h	4	213	-0.86 (-1.37 to -0.36)	78	Low
24 h	13	895	-0.39 (-0.60 to -0.17)	79	Low
48 h	11	667	-0.47 (-0.77 to -0.17)	85	Very Low
72 h	8	514	-0.95 (-1.36 to -0.54)	81	Low
7 d	7	474	-0.56 (-0.86 to -0.26)	72	Low
14 d	2	112	-0.50 (-0.76 to -0.24)	0	Moderate
Function					
HSS	6	507	3.96 (1.60 to 6.32)	91	Low
KSS	3	212	7.33 (1.22 to 13.45)	86	Very Low
Rom of knee	6	329	5.61 (4.08 to 7.14)	61	Low
Analgesia-related adverse effects	12	744	0.30 (0.20 to 0.45)	0	Moderate
CRP	3	170	-0.92 (-1.57 to -0.27)	71	Low
IL-6	4	354	-1.29 (-2.07 to -0.51)	87	Low

Table 2. Main findings of meta-analysis of TEAS on rehabilitation after TKA

we performed subgroup analyses according to the time of postoperative outcome testing. The subgroup analysis was performed to evaluate effect of TEAS on the VAS at 6, 12, 24, 48, 72 hours, 7 and 14 days after TKA operation. In comparison to the CG, Figure 3 showed that the EG had a significant reduction in pain at post-operative 6 h [MD = -0.86 (95% CI: -1.35, -0.37), P = 0.0006, I² = 91%], 12 h [MD = -0.86 (95% CI: -1.37, -0.36), P = 0.0008, I² = 78%], 24 h [MD = -0.39 (95% CI: -0.60, -0.17), P = 0.0004, $l^2 = 79\%$], 48 h [MD = -0.47 (95% CI: -0.77, -0.17), P = 0.002, $l^2 = 85\%$], 72 h [MD = $-0.95 (95\% \text{ Cl}: -1.36, -0.54), P < 0.00001, I^2 =$ 81%], 7 days [MD = -0.56 (95% CI: -0.86, -0.26), P = 0.0002, $I^2 = 72\%$], and 14 days [MD = -0.50] $(95\% \text{ CI}: -0.76, -0.24), P = 0.0002, I^2 = 0\%].$

Functional score: Eight studies reported knee function using different instruments including Hospital for Special Surgery Knee Score (HSS) and knee society score (KSS), with 359 participants in the EG and 360 participants in the the CG overall. Six studies reported post-treatment HSS scores with 253 patients in the EG and 254 patients in the CG. HSS scores were statistically higher in the EG than in the CG [MD = 3.96 (95% CI: 1.60, 6.32), P = 0.001, $I^2 = 91\%$]. Three studies reported post-treatment KSS scores with 106 patients in the EG and 106 patients in the CG. The result indicated that the KSS score of EG improved more than that of CG [MD = 7.33 (95% CI: 1.22, 13.45), P = 0.02, $l^2 = 86\%$]. Meta-analysis and forest plots are shown in **Figure 4**.

ROM of knee: A total of six studies, with 166 participants in the control groups and 163 in the experimental groups, reported the efficacy of TEAS for ROM of knee after TKA. The analysis result revealed a significant difference in ROM of knee between EG and CG [MD = 5.61 (95% CI: 4.08, 7.14), P < 0.00001, $I^2 = 61\%$], with substantial heterogeneity, using a randomeffects model (**Figure 5**).

Nausea/vomiting (analgesia-related adverse effect): Twelve studies reported the occurrence of analgesia-related adverse effects with 374 participants in the EG and 370 participants in the CG. Meta-analysis results showed a substantial difference between the EG and the CG [OR = 0.30 (95% Cl: 0.20, 0.45), P < 0.00001, $l^2 = 0\%$], with no heterogeneity, using a fixed-effects model (**Figure 6**).

Relevant serum indexes including IL-6, CRP: A total of five trials reported TEAS intervention for efficacy of inflammation indicators including Interleukin-6 (IL-6) and C-reactive protein (CRP) after TKA operation. A pooled meta-analysis of four studies with 254 participants showed that there was a meaningful variation in the degree of IL-6 improvement IL-6 between the EG and the CG [SMD = -0.92 (95% CI: -1.57, -0.27), P =

		FC			~~			Maan Difference	Noon Difference
Study or Subgroup	Mean	EG SD	Total	Mean	CG SD	Total	Weight	Mean Difference IV. Random. 95% CI	Mean Difference IV. Random. 95% Cl
1.1.1 Pain (6h)			12491004	10000000		0.92504			
Hu 2021		0.78	50		0.53	50	2.4%	-1.43 [-1.69, -1.17]	
Tong 2020		0.47	20 34	3.62	0.43 0.79	20 32	2.4% 2.0%	-0.38 [-0.66, -0.10] -0.38 [-0.85, 0.09]	
Wang(a) 2021 Wang 2022		1.14	24	3.81	1.35	24	1.6%	-1.69 [-2.39, -0.99]	
Zhang(a) 2019	3.3		40	3.9	0.6	40	2.4%	-0.60 [-0.84, -0.36]	
Subtotal (95% CI)			168			166	10.8%	-0.86 [-1.35, -0.37]	◆
Heterogeneity: Tau ² = Test for overall effect:				= 4 (P	< 0.00	001); l²	= 91%		
1.1.2 Pain (12h)									
Bai 2018	5.4	1.73	20	6.95	1.47	20	1.1%	-1.55 [-2.54, -0.56]	
Tong 2020		0.43	20		0.68	20	2.2%	-0.47 [-0.82, -0.12]	
Wang(a) 2021		1.38	34		0.91	32	1.8%	-0.47 [-1.03, 0.09]	
Zhang 2021 Subtotal (95% CI)	5.06	0.76	32 106	6.28	0.52	35 107	2.3% 7.5%	-1.22 [-1.53, -0.91] -0.86 [-1.37, -0.36]	
Heterogeneity: Tau ² = Test for overall effect:			3.43, df	= 3 (P	= 0.00			-0.00[-1.07, -0.00]	
	2 = 3.35	5 (P = t	.0008)						
1.1.3 Pain (24h)	10	4.04		E 05	4 50	-	4 004	1	
Bai 2018 Bai 2023	4.3	1.34 1.5	20 71	5.85	1.53 1.51	20 69	1.2% 1.9%	-1.55 [-2.44, -0.66] -0.32 [-0.82, 0.18]	
Chen 2019	5.2		25	5.84	0.9	25	1.8%	-0.64 [-1.23, -0.05]	
Hu 2021		0.43	50		0.53	50	2.5%	-0.46 [-0.65, -0.27]	
Tong 2020		0.46	20		0.77	20	2.2%	-0.10 [-0.49, 0.29]	
Wang(a) 2021	2.6		34		0.72	32	2.2%	-0.78 [-1.15, -0.41]	
Wang(b) 2021	6.97 1.31	0.8 0.54	31 24	7.06	0.96	31 24	2.1% 1.8%	-0.09 [-0.53, 0.35]	
Wang 2022 Xie 2021	1.31	0.54	41	3.66	0.69	24	1.8%	-1.00 [-1.57, -0.43] -0.05 [-0.36, 0.26]	
Zhang(a) 2019	2.6	0.75	40	2.6	0.6	40	2.4%	0.00 [-0.24, 0.24]	+
Zhang(b) 2019	2.2	1.7	30	1.1	1.5	30	1.4%	1.10 [0.29, 1.91]	
Zhang 2021		0.71	32		0.69	35	2.3%	-0.89 [-1.23, -0.55]	
Zhuang 2019	2.43	0.24	30	2.83	0.48	30	2.5%	-0.40 [-0.59, -0.21]	
Subtotal (95% CI)	0 14: 0	hi2 - 51	448	- 10 /5		447	26.6%	-0.39 [-0.60, -0.17]	•
Heterogeneity: Tau ² = Test for overall effect:				- 12 (F	< 0.0	0001); 1	= 79%		
1.1.4 Pain (48h)									
Bai 2018		1.28	20		1.31	20	1.4%	-1.95 [-2.75, -1.15]	
Chen 2019	3.4		25	4.16	0.69	25	2.0%	-0.76 [-1.25, -0.27]	
Cui 2021		0.95	20	6.95	1	20	1.7%	-0.90 [-1.50, -0.30]	
Hu 2021		0.45	50		0.52	50	2.5%	-0.19 [-0.38, 0.00]	
Li 2021 Tong 2020	6.7 2.27		20 20	2.31	1.35 0.58	20 20	1.4% 2.2%	0.35 [-0.42, 1.12] -0.04 [-0.40, 0.32]	-
Wang(a) 2021	2.18		34	2.34		32	2.2%	-0.16 [-0.52, 0.20]	-+
Wang(b) 2021	7.71	0.97	31	8.48	0.68	31	2.1%	-0.77 [-1.19, -0.35]	
Xie 2021	3.39	0.77	41	3.32	0.72	41	2.3%	0.07 [-0.25, 0.39]	+-
Zhang(a) 2019	1.5	0.7	40	1.6	0.8	40	2.3%	-0.10 [-0.43, 0.23]	
Zhang 2021	3.78	0.71	32	4.89	0.53	35	2.3%	-1.11 [-1.41, -0.81]	
Subtotal (95% CI) Heterogeneity: Tau ² =	0.20. 0	hi² = 67	333 7 84 df	= 10 /5	< 0.0	334 0001): I	22.5% ² = 85%	-0.47 [-0.77, -0.17]	· ·
Test for overall effect:				- 10 (F	- 0.0	0001), 1	- 00%		
1.1.5 Pain (72h)									
Bai 2018	3.05	1.23	20	4.45	1.47	20	1.3%	-1.40 [-2.24, -0.56]	
Bai 2023	5.32		71	6.04	1.82	69	1.7%	-0.72 [-1.33, -0.11]	
Chen 2019	2.44		25	2.96	0.54	25	2.1%	-0.52 [-0.92, -0.12]	
Cui 2021		0.82	20 20	5.4		20 20	1.9%	-0.80 [-1.33, -0.27]	
Li 2021 Wang(b) 2021	3.75	1.48 1.61	31		1.47 1.11	31	1.2% 1.6%	-1.20 [-2.11, -0.29] -0.80 [-1.49, -0.11]	
Xie 2021		0.61	41		0.86	41	2.3%	-0.52 [-0.84, -0.20]	
Zhuang 2019	3.4		30		0.79	30	2.3%	-1.77 [-2.10, -1.44]	
Subtotal (95% CI)			258			256	14.4%	-0.95 [-1.36, -0.54]	•
Heterogeneity: Tau ² = Test for overall effect:					< 0.00	001); l²	= 81%		
1.1.6 Pain (7d)									
Bai 2023	2.89	1.5	71	3.67	1.86	69	1.8%	-0.78 [-1.34, -0.22]	
Chen 2019		1.01	25		1.04	25	1.8%	-0.88 [-1.45, -0.31]	
Cui 2021	2.85	0.35	20	3.35	0.75	20	2.2%	-0.50 [-0.86, -0.14]	
Li 2021	2.45	1.1	20		1.19	20	1.5%	-1.00 [-1.71, -0.29]	
Wang(b) 2021		0.95	31		1.28	31	1.8%	-0.22 [-0.78, 0.34]	
Xie 2021 Zhuang 2019		0.61 0.35	41 30		0.88	41 30	2.3% 2.5%	-0.76 [-1.09, -0.43] -0.10 [-0.30, 0.10]	
Subtotal (95% CI)	2.13	0.35	238	2.23	0.43	236	2.5%	-0.56 [-0.86, -0.26]	•
Heterogeneity: Tau ² = Test for overall effect:			1.35, df	= 6 (P	= 0.00				
			(0002)						
1.1.7 Pain (14d) Kim 2021	2.27	0.8	15	2 97	0.64	15	1.9%	-0.60 [-1.12 -0.09]	
Xie 2021		0.8	15	2.87	0.64	15	1.9%	-0.60 [-1.12, -0.08] -0.46 [-0.76, -0.16]	
Subtotal (95% CI)	2.10	0.00	56	2.01	0.1	56	4.2%	-0.50 [-0.76, -0.24]	◆
Heterogeneity: Tau ² =			21, df =	1 (P =	0.65);				
Test for overall effect:	2 = 3.73	s (P = 0	0.0002)						
Total (95% CI)			1607				100.0%	-0.60 [-0.74, -0.47]	, • •
Heterogeneity: Tau ² =					P < 0.	00001);	l ² = 84%	-	-2 -1 0 1 2
Test for overall effect: Test for subgroup diffe					= 0.1	6) 12 -	35 1%		Favours [EG] Favours [CG]
reactor subgroup diffe	sterices:	Gui- E	3.24. 0	, – 0 (P	- 0.1		33.170		

Figure 3. Meta-analysis and forest plot and for postoperative pain at different periods.

0.001, $l^2 = 71\%$], with high heterogeneity, using a random-effects model (**Figure 7**). Regarding

CRP, a meta-analysis including 3 studies showed lower postoperative CPR in the EG than in

		EG			CG			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	IV, Random, 95% CI
2.1.1 HSS							-		
Bai 2023	91.29	5.97	71	88.29	6.54	69	12.0%	3.00 [0.92, 5.08]	
Li 2021	67.75	4.06	20	61.5	4.96	20	11.0%	6.25 [3.44, 9.06]	
Liang 2017	72.77	6.56	40	69.53	5.61	40	11.2%	3.24 [0.57, 5.91]	_ _
Wu 2017	82.13	6.66	60	74.28	3.57	60	12.2%	7.85 [5.94, 9.76]	
Zhang 2021	84.03	1.77	32	83.4	1.7	35	13.3%	0.63 [-0.20, 1.46]	-
Zhuang 2019	68.53	2.05	30	65.2	3.31	30	12.8%	3.33 [1.94, 4.72]	
Subtotal (95% CI)			253			254	72.4%	3.96 [1.60, 6.32]	\bullet
Heterogeneity: Tau ² =	7.65; Cł	ni² = 58	3.16, df	= 5 (P ·	< 0.000	01); l² =	= 91%		
Test for overall effect:	Z = 3.29) (P = (0.001)						
2.1.2 KSS									
Li 2019	86.03	6.58	25	72.58	11.27	25	7.6%	13.45 [8.33, 18.57]	
Liang 2017	71.71	4.41	40	68.96	6.29	40	11.6%	2.75 [0.37, 5.13]	
Xie 2021	73.76	9.57	41	67	11.22	41	8.4%	6.76 [2.25, 11.27]	
Subtotal (95% CI)			106			106	27.6%	7.33 [1.22, 13.45]	
Heterogeneity: Tau ² = 2	24.82; 0	Chi² = '	14.49, d	if = 2 (P	= 0.00	07); l² =	= 86%		
Test for overall effect:	Z = 2.35	6 (P = 0	0.02)						
Total (95% CI)			359			360	100.0%	4.78 [2.66, 6.90]	●
Heterogeneity: Tau ² =	8.60; Cł	ni² = 78	3.84, df	= 8 (P	< 0.000	01); l² =	= 90%		
Test for overall effect:	Z = 4.42	2 (P < (0.0000	I) È					-20 -10 0 10 20
Test for subgroup diffe	rences:	Chi ² =	1.02, 0	if = 1 (P	= 0.31), l² = 1	.8%		Favours [CG] Favours [EG]

Figure 4. Meta-analysis and forest plot for function.



	EG		CG			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
Bai 2018	1	20	5	20	5.1%	0.16 [0.02, 1.50]	
Bai 2023	3	71	11	69	11.6%	0.23 [0.06, 0.87]	
Chen 2019	2	25	9	25	9.0%	0.15 [0.03, 0.81]	
Cui 2021	3	20	6	20	5.5%	0.41 [0.09, 1.95]	
Hu 2021	5	50	6	50	5.8%	0.81 [0.23, 2.87]	
Li 2021	1	20	6	20	6.2%	0.12 [0.01, 1.14]	
Tong 2020	3	20	7	20	6.4%	0.33 [0.07, 1.52]	
Wang(a) 2021	5	34	12	32	11.4%	0.29 [0.09, 0.94]	
Wang 2019	4	20	7	20	6.1%	0.46 [0.11, 1.94]	
Wang 2022	2	24	7	24	6.9%	0.22 [0.04, 1.20]	
Zhang(a) 2019	9	40	22	40	18.5%	0.24 [0.09, 0.63]	_
Zhang(b) 2019	4	30	8	30	7.5%	0.42 [0.11, 1.60]	
Total (95% CI)		374		370	100.0%	0.30 [0.20, 0.45]	◆
Total events	42		106				
Heterogeneity: Chi ² =	5.25, df =	11 (P =	0.92); l ²	= 0%			
Test for overall effect:		•	<i>,</i> .				0.02 0.1 1 10 50 Favours [EG] Favours [CG]

Figure 5. Meta-analysis and forest plot for range of motion (ROM) of knee.

Figure 6. Meta-analysis and forest plot for analgesia-related adverse effects.



Figure 7. Meta-analysis and forest plot and for Interleukin-6.



Figure 8. Meta-analysis and forest plot and for C-reactive protein.

the CG [SMD = -1.29 (95% CI: -2.07, -0.51), *P* = 0.005, *l*² = 87%], with significant heterogeneity, using a random-effects model (**Figure 8**).

Sensitivity analysis

Sensitivity analyses of the primary outcomes were performed by removing trials "one-at-a-time" to identify the source(s) of heterogeneity, which revealed that there were overall stable heterogeneities and results (<u>Supplementary Table 2</u>).

Publication bias

The funnel plot for the VAS and functional score was symmetric as presented in <u>Supplementary</u> Figure 1. Begg and Eggers' tests indicated that there was no significant publication bias in the included studies (<u>Supplementary Table 3</u>).

Evidence quality assessment

Evidence quality was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation (i.e., "GRADE") system. A brief summary of the results is presented in <u>Supplementary Figure 2</u>.

Discussion

Total knee arthroplasty (TKA) is indicated for patients with advanced osteoarthritis of the

knee that has not responded to conservative treatment and significantly limits daily activity [43]. Accelerating recovery after TKA has been a long-standing concern. TEAS has become an essential interventional modality in the perioperative period, offering various benefits to promote postoperative recovery, including pain reduction, gastrointestinal modulation, antiinflammatory effects, and stress reduction [44, 45]. We found that most of the included studies had a follow-up time of less than one month. thus the efficacy of TEAS for long-term rehabilitation after TKA is still not clear, and the followup time needs to be further increased in future clinical trials. Current clinical trials of TEAS for postoperative rehabilitation after TKA vary in acupuncture points, duration of intervention, and settimngs of electrical stimulation, a situation that limits their expansion in clinical practice and requires further standardization of these treatment protocols. A previous metaanalysis showed that acupuncture achieved significant improvement in relieving early pain and reducing nausea/vomiting after TKA. However, the improvement in knee ROM was not significant [46]. Compared to the previous meta-analysis, it was found that TEAS was more effective than acupuncture in improving knee ROM after TKA. Meta-analysis by Zhu [47] showed that TENS supplementation intervention was found to significantly reduce pain and

morphine requirement over a 24-hour period and promote functional recovery in patients who had undergone TKA. This study demonstrated that TEAS, a therapy that combines the benefits of acupuncture and TENS, not only improved analgesia but also enhanced knee motor function and anti-inflammatory effects, and reduced the incidence of analgesia-related adverse effects.

Postoperative pain management

Postoperative pain management is essential for rehabilitation and to enhance recovery in patients undergoing TKA [48]. In terms of functional status and quality of life, TKA provides substantial improvement for patients. However, there is evidence that approximately 8% to 34% of postoperative pain will develop into chronic pain [49]. With 3.48 million TKA surgeries projected to be performed annually in the United States by 2030, up to 500,000 patients per year could develop chronic postoperative pain [50]. In this review, we investigated the influence of TEAS on short-term postoperative pain relief and relevant serum inflammatory indexes. Our results revealed that patients treated with TEAS (experimental group EG) demonstrated substantial improvement in pain compared with control group CG at 6, 12, 24, 48, and 72 h and 7 and 14 days after TKA. In addition, we found that TEAS reduced IL-6 and CRP levels at an early stage after TKA surgery. Amelioration of early pain may be associated with the efficacy of TEAS in reducing the local inflammatory response in the knee joint. Nevertheless, the efficacy of TEAS for long-term pain control after knee replacement remains unclear.

With a history exceeding 3000 years, acupuncture has been used extensively in Chinese health care. TEAS is a non-invasive type of electrical acupuncture stimulation developed from the technology of acupuncture, which is widely accepted and used for postoperative pain worldwide [51]. However, the mechanisms underlying the analgesic effects of TEAS have not been clearly elucidated. Some research has shown that TEAS can exert an interventional effect on pain sensation through multiple mechanisms: (1) TEAS may have analgesic effects through enhancement of the release of endogenous opioid peptides and inhibiting the production of endogenous pain mediators [52]; (2) TEAS relieves postoperative immune damage and decreases levels of the tumor necrosis factor- α (TNF- α) and cytokines interleukin-1 β (IL-1 β) in the peripheral circulation [53]; (3) TEAS prevents early neuropathic pain sensitization at the peripheral level [54].

Function

Functional scores and ROM of the knee joint reflect the recovery of knee function after TKA surgery. The HSS and KSS values are reliable for assessing knee dysfunction, including pain, joint function, and muscle strength, and are widely used to evaluate the outcome of TKA [55, 56]. Eight studies in this meta-analysis evaluated functional scores, and the subgroup analysis of rating scale type indicated that TEAS had a substantial benefit in rehabilitation compared to a CG, whether measured by the HSS score or the KSS score. Range of motion reflects the degree of joint stiffness and plays an essential role in helping to restore knee function. Knee ROM was reported in six studies, and the analysis result showed that TEAS significantly improved the rehabilitation of knee ROM compared to the CG.

Analgesia-related adverse effects

Painkillers are widely used after surgery, mostly to minimize physical and psychological discomfort and speed recovery, but the side effects of painkillers often impair patient recovery [57]. Analgesics have numerous side effects ranging from bothersome to life-threatening, including nausea, vomiting, constipation, pruritus, drowsiness, and respiratory depression [58]. The prevalence and severity of adverse effects associated with analgesia are such that they cannot go unnoticed [59]. Of these, nausea and vomiting are the most frequent. TEAS greatly reduced the incidence of nausea/vomiting after TKA surgery compared to the control group in this study. In addition, the choice of acupuncture points is an essential element of TEAS treatment. In terms of the selection of acupoints for TEAS treatment, PC6 (Neiguan) and LI4 (Hegu) were the most frequently selected acupuncture points in the included studies. Studies to date indicate that stimulation of LI4 (Hegu) and PC6 (Neiguan) may decrease the incidence of nausea and vomiting [60]. SP9 (n = 9), SP10 (n = 9), LI4 (n = 8), and PC6 (n = 8)

were the four most commonly used acupoints in the included studies. We believe that SP9, SP10, LI4, and PC6 are the best combinations of acupuncture points according to the review.

Some limitations of the present study should be addressed. First, the results of long-term follow-up are not known because the observation time point in the included trials was mostly < 28 days postoperative. Second, the acupuncture points, intervention time, and electrical stimulation parameters were inconsistent, which could have led to a high degree of heterogeneity and affected the results. Third, some of the studies had a small sample size and were of low quality, which had a negative impact on the strength of the evidence supporting the research findings. Therefore, to draw firmer conclusions, high-quality, large-sample, multicenter RCTs are needed in the future.

In conclusion, we systematically evaluated the effects of TEAS on postoperative rehabilitation in TKA patients. Our results suggest that the performance of TEAS in TKA patients was associated with early postoperative pain reduction, improved knee function, and reduced adverse effects of analgesics. While stronger evidence is required to determine the best method to apply TEAS approach in clinical practice, our findings support the use of TEAS therapy during the clinical practice for early TKA postoperative rehabilitation.

Acknowledgements

This research was funded by China Postdoctoral Science Foundation (2023M731070), Hunan Provincial Science and Technology Department (2023JJ60118), Hunan University of Traditional Chinese Medicine Graduate Student Innovation Projects (2023CX18), and Hunan Academy of Chinese Medicine (202129).

Disclosure of conflict of interest

None.

Address correspondence to: Liang Ou and Jianjun Kuang, Hunan Academy of Chinese Medicine, No. 142, Yuehua Road, Yuelu District, Changsha 410013, Hunan, China. Tel: +86-0731-89949006; E-mail: ouliang2020@163.com (LO); kuangjianjun@ hnucm.edu.cn (JJK)

References

- [1] Riewruja K, Phakham S, Sompolpong P, Reantragoon R, Tanavalee A, Ngarmukos S, Udomsinprasert W, Suantawee T, Dechsupa S and Honsawek S. Cytokine profiling and intra-articular injection of autologous platelet-rich plasma in knee osteoarthritis. Int J Mol Sci 2022; 23: 890.
- [2] Motta F, Barone E, Sica A and Selmi C. Inflammaging and osteoarthritis. Clin Rev Allergy Immunol 2023; 64: 222-238.
- [3] Abhari S, Hsing TM, Malkani MM, Smith AF, Smith LS, Mont MA and Malkani AL. Patient satisfaction following total knee arthroplasty using restricted kinematic alignment. Bone Joint J 2021; 103-B: 59-66.
- [4] Brown MJ, Matthews JR, Bayers-Thering MT, Phillips MJ and Krackow KA. Low incidence of postoperative complications with navigated total knee arthroplasty. J Arthroplasty 2017; 32: 2120-2126.
- [5] Li JW, Ma YS and Xiao LK. Postoperative pain management in total knee arthroplasty. Orthop Surg 2019; 11: 755-761.
- [6] Bosch DJ, Nieuwenhuijs-Moeke GJ, van Meurs M, Abdulahad WH and Struys MMRF. Immune modulatory effects of nonsteroidal anti-inflammatory drugs in the perioperative period and their consequence on postoperative outcome. Anesthesiology 2022; 136: 843-860.
- [7] Demasi M, Segall M, Mengotto A, Cuartas P, Feiertag N, Loloi J, Ahn J, Kim M, Laudano M, Stern J and Watts K. Optimizing pain management following kidney stone surgery: can we avoid narcotics? World J Urol 2022; 40: 3061-3066.
- [8] Kurosaka K, Tsukada S, Ogawa H, Nishino M, Nakayama T, Yoshiya S and Hirasawa N. Addition of corticosteroid to periarticular injections reduces postoperative pain following total hip arthroplasty under general anaesthesia: a double-blind randomized controlled trial. Bone Joint J 2020; 102-B: 1297-1302.
- [9] Wongrakpanich S, Wongrakpanich A, Melhado K and Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis 2018; 9: 143-150.
- [10] Li JX. Combining opioids and non-opioids for pain management: current status. Neuropharmacology 2019; 158: 107619.
- [11] Beck H, Beyer F, Gering F, Günther KP, Lützner C, Walther A and Stiehler M. Sports therapy interventions following total hip replacement. Dtsch Arztebl Int 2019; 116: 1-8.
- [12] Ko HF, Chen CH, Dong KR and Wu HC. Effects of acupuncture on postoperative pain after total knee replacement: systematic literature re-

view and meta-analysis. Pain Med 2021; 22: 2117-2127.

- [13] Peng L, Wang K, Zeng Y, Wu Y, Si H and Shen B. Effect of neuromuscular electrical stimulation after total knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne) 2021; 8: 779019.
- [14] Lan F, Ma YH, Xue JX, Wang TL and Ma DQ. Transcutaneous electrical nerve stimulation on acupoints reduces fentanyl requirement for postoperative pain relief after total hip arthroplasty in elderly patients. Minerva Anestesiol 2012; 78: 887-895.
- [15] Qu F, Li R, Sun W, Lin G, Zhang R, Yang J, Tian L, Xing GG, Jiang H, Gong F, Liang XY, Meng Y, Liu JY, Zhou LY, Wang SY, Wu Y, He YJ, Ye JY, Han SP and Han JS. Use of electroacupuncture and transcutaneous electrical acupoint stimulation in reproductive medicine: a group consensus. J Zhejiang Univ Sci B 2017; 18: 186-193.
- [16] Wang H, Xie Y, Zhang Q, Xu N, Zhong H, Dong H, Liu L, Jiang T, Wang Q and Xiong L. Transcutaneous electric acupoint stimulation reduces intra-operative remifentanil consumption and alleviates postoperative side-effects in patients undergoing sinusotomy: a prospective, randomized, placebo-controlled trial. Br J Anaesth 2014; 112: 1075-1082.
- [17] Szmit M, Agrawal S, Goździk W, Kübler A, Agrawal A, Pruchnicki P, Woźniak M, Nowak M, Bartoszewicz B and Rudnicki J. Transcutaneous electrical acupoint stimulation reduces postoperative analgesic requirement in patients undergoing inguinal hernia repair: a randomized, placebo-controlled study. J Clin Med 2021; 10: 146.
- [18] Zhang Q, Gao Z, Wang H, Ma L, Guo F, Zhong H, Xiong L and Wang Q. The effect of pre-treatment with transcutaneous electrical acupoint stimulation on the quality of recovery after ambulatory breast surgery: a prospective, randomised controlled trial. Anaesthesia 2014; 69: 832-839.
- [19] Hauer K, Wendt I, Schwenk M, Rohr C, Oster P and Greten J. Stimulation of acupoint ST-34 acutely improves gait performance in geriatric patients during rehabilitation: a randomized controlled trial. Arch Phys Med Rehabil 2011; 92: 7-14.
- [20] Hei J, Han X and Dai B. A commentary on "transcutaneous electrical acupoint stimulation for preventing postoperative nausea and vomiting after general anesthesia: a metaanalysis of randomized controlled trials" (Int J Surg 2020; 73: 57-64). Int J Surg 2022; 104: 106710.

- [21] Page MJ, Mckenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, Mcdonald S, Mcguinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P and Moher D. The prisma 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol 2021; 134: 178-189.
- [22] Higgins JPT, Thomas J and Chandler J. Cochrane handbook for systematic reviews of interventions version 6.2 (2021). Available online at: www.training.cochrane.org/handbook (accessed February 2021); 2021.
- [23] Liang YY, Guo YM, Zhou SL, Cen J, Li DH and Chen H. Application of transcutaneous electric acupoint stimulation combined with conventional rehabilitation therapy to early rehabilitation after total knee arthroplasty. J Trad Chin Orthop Trauma 2017; 29: 35-39.
- [24] Wu ZQ, Xu KN, Xie JJ, Song JY, Yang GF, Wang D and Yang F. Study on the improvement of pain after total knee arthroplasty by transdermal electrical stimulation of acupoints. Journal of Shandong University of TCM 2017; 41: 244-246.
- [25] Bai B. Clinical study on pain control after total knee arthroplasty by transcutaneous electrical acupoint stimulation combined with cocktail therapy. Shandong, Shandong University of Traditional Chinese Medicine 2018.
- [26] Zhang PH, Liu P, Li HZ, Wang MJ, Zhao S, Li Z and Zhao S. Effect of percutaneous acupoint electrical stimulation on patient-controlled intravenous analgesia in elderly patients after total knee arthroplasty. J Clin Anesthesiol 2019; 35: 243-246.
- [27] Zhuang Y. Study on the effect of transcutaneous electrical acupoint stimulation on eras after tka. Shandong, Shandong University of Traditional Chinese Medicine 2019.
- [28] Chen PP, Xie WP, Lv WX, Yan B and Qiu HM. Clinical study of transcutaneous electrical acupoint stimulation to alleviate limb pain after total knee arthroplasty. World Chinese Medicine 2019; 14: 1586-1589.
- [29] Zhang LH. Effect of teas aided anesthesia on T-lymphocyte subsets in elderly patients with total knee arthroplasty and its role in postoperative outcome. Shanxi, Shanxi Medical University 2019.
- [30] Li YL. A randomized controlled trial on transcutaneous electrical acupoints stimulation for acute pain after the total knee arthroplasty. Shanghai, Shanghai University of Traditional Chinese Medicine 2019.
- [31] Wang GR. Clinical efficacy of transcutaneous electrical acupoint stimulation in perioperative

period of total knee arthroplasty. Hebei, Hebei Medical University 2019.

- [32] Tong L. Effects of transcutaneous electrical acupoint stimulation combined with dexmedetomidine on T lymphocyte subsets and postoperative recovery in patients undergoing total knee arthroplasty. Shanxi, Shanxi Medical University 2020.
- [33] Kim B, Lohman E and Yim J. Acupuncture-like transcutaneous electrical nerve stimulation for pain, function, and biochemical inflammation after total knee arthroplasty. Altern Ther Health Med 2021; 27: 28-34.
- [34] Wang CR. Effect of transcutaneous electrical acupoint stimulation on perioperative neurocognitive dysfunction and postoperative rehabilitation in elderly patients undergoing total knee arthroplasty. Shanxi, Shanxi Medical University 2021.
- [35] Wang H. Auxiliary analgesia effect of transcutaneous electricalacupoint stimulation on patients after total knee arthroplasty. Shandong, Shandong University of Traditional Chinese Medicine 2021.
- [36] Li S. Clinical observation on analgesic effect of differentintensity transcutaneous electrical acupoint stimulationafter total knee arthroplasty. Shandong, Shandong University of Traditional Chinese Medicine 2021.
- [37] Hu XX, Li JS, Jin Y, Xu ML, He JW and Liang YY. Clinical study on preemptive analgesia effect of transcutaneous electrical acupoint stimulation during first total knee arthroplasty in elderly patients with osteoarthritis. Shandong Journal of TCM 2021; 40: 724-728.
- [38] Cui XM. Clinical evaluation of transcutaneous electrical acupointstimulation combined with femoral nerve block forpostoperative analgesia after total knee arthroplasty. Shandong, Shandong University of Traditional Chinese Medicine 2021.
- [39] Xie R. Effect of transcutaneous electrical acupoint stimulation on functional rehabilitation after total knee arthroplasty. Beijing, Beijing University of Traditional Chinese Medicine 2021.
- [40] Zhang XN. Effects of transcutaneous electrical acupoints stimulation on perioperative pain and hemorheology of total knee arthroplasty under eras pathway. Tianjin, Tianjin University of Traditional Chinese Medicine 2021.
- [41] Wang WJ and Ma LP. Effect of transcutaneous electrical acupoint stimulation on cognitive function in elderly patients undergoing total knee arthroplasty under general anesthesia. Chinese Science and Technology Periodical Database (Citation Edition) Medical Health 2022; 3: 57-60.

- [42] Bai TY, Qiu JM, Li ZG, Wei YF, Wen GN, Liang PW and Liang PW. Effects of transcutaneous electrical acupoint stimulation on adjuvant analgesia and plasma β -endorphin in patients after total knee arthroplasty. Chinese Journal of Information on TCM 2023; 30: 141-145.
- [43] Hannon CP, Goodman SM, Austin MS, Yates A Jr, Guyatt G, Aggarwal VK, Baker JF, Bass P, Bekele DI, Dass D, Ghomrawi HMK, Jevsevar DS, Kwoh CK, Lajam CM, Meng CF, Moreland LW, Suleiman LI, Wolfstadt J, Bartosiak K, Bedard NA, Blevins JL, Cohen-Rosenblum A, Courtney PM, Fernandez-Ruiz R, Gausden EB, Ghosh N, King LK, Meara AS, Mehta B, Mirza R, Rana AJ, Sullivan N, Turgunbaev M, Wysham KD, Yip K, Yue L, Zywiel MG, Russell L, Turner AS and Singh JA. 2023 American College of Rheumatology and American Association of Hip and Knee Surgeons clinical practice guideline for the optimal timing of elective hip or knee arthroplasty for patients with symptomatic moderate-to-severe osteoarthritis or advanced symptomatic osteonecrosis with secondary arthritis for whom nonoperative therapy is ineffective. Arthritis Care Res (Hoboken) 2023; 75: 2227-2238.
- [44] Li H, Du C, Lu L, Hu X, Xu H, Li N, Liu H and Wen Q. Transcutaneous electrical acupoint stimulation combined with electroacupuncture promotes rapid recovery after abdominal surgery: study protocol for a randomized controlled trial. Front Public Health 2022; 10: 1017375.
- [45] Finberg M, Braham R, Goodman C, Gregory P and Peeling P. Effects of electrostimulation therapy on recovery from acute team-sport activity. Int J Sports Physiol Perform 2013; 8: 293-299.
- [46] Chen Z, Shen Z, Ye X, Xu Y, Liu J, Shi X, Chen G, Wu J, Chen W, Jiang T, Liu W and Xu X. Acupuncture for rehabilitation after total knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne) 2021; 7: 602564.
- [47] Zhu Y, Feng Y and Peng L. Effect of transcutaneous electrical nerve stimulation for pain control after total knee arthroplasty: a systematic review and meta-analysis. J Rehabil Med 2017; 49: 700-704.
- [48] Lavand'Homme PM, Kehlet H, Rawal N and Joshi GP; PROSPECT Working Group of the European Society of Regional Anaesthesia and Pain Therapy (ESRA). Pain management after total knee arthroplasty: procedure specific postoperative pain management recommendations. Eur J Anaesthesiol 2022; 39: 743-757.
- [49] Kim DH, Pearson-Chauhan KM, Mccarthy RJ and Buvanendran A. Predictive factors for de-

veloping chronic pain after total knee arthroplasty. J Arthroplasty 2018; 33: 3372-3378.

- [50] Inacio MCS, Paxton EW, Graves SE, Namba RS and Nemes S. Projected increase in total knee arthroplasty in the United States - an alternative projection model. Osteoarthritis Cartilage 2017; 25: 1797-1803.
- [51] Lu Z, Wang Q, Sun X, Zhang W, Min S, Zhang J, Zhao W, Jiang J, Wang Y, Zhu Y, Zheng L, Wang Y, Guo Y, Zhang L, Wang L, Lei C, Liu T, Yang X, Zhang J, Li C, Zhang N, Dong H and Xiong L. Transcutaneous electrical acupoint stimulation before surgery reduces chronic pain after mastectomy: a randomized clinical trial. J Clin Anesth 2021; 74: 110453.
- [52] Ma X, Chen W, Yang NN, Wang L, Hao XW, Tan CX, Li HP and Liu CZ. Potential mechanisms of acupuncture for neuropathic pain based on somatosensory system. Front Neurosci 2022; 16: 940343.
- [53] Zhang T, Ou L, Chen Z, Li J, Shang Y and Hu G. Transcutaneous electrical acupoint stimulation for the prevention of postoperative cognitive dysfunction: a systematic review and meta-analysis. Front Med (Lausanne) 2021; 8: 756366.
- [54] Lin YW, Chou AIW, Su H and Su KP. Transient receptor potential v1 (TRPV1) modulates the therapeutic effects for comorbidity of pain and depression: the common molecular implication for electroacupuncture and omega-3 polyunsaturated fatty acids. Brain Behav Immun 2020; 89: 604-614.

- [55] Sershon RA, Fricka KB, Hamilton WG, Nam D, Parks NL, Debenedetti A and Della Valle CJ. Early results of a randomized controlled trial of partial versus total knee arthroplasty. J Arthroplasty 2022; 37: S94-S97.
- [56] Ao Y, Guo L, Chen H, He R, Yang P, Fu D, Gu L, Peng Y, Xiong R, Yang L and Wang F. Application of three-dimensional-printed porous tantalum cones in total knee arthroplasty revision to reconstruct bone defects. Front Bioeng Biotechnol 2022; 10: 925339.
- [57] Wick EC, Grant MC and Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review. JAMA Surg 2017; 152: 691-697.
- [58] Hemmings HC Jr and Lambert DG. The good, the bad, and the ugly: the many faces of opioids. Br J Anaesth 2019; 122: 705-707.
- [59] Bicket MC, Long JJ, Pronovost PJ, Alexander GC and Wu CL. Prescription opioid analgesics commonly unused after surgery: a systematic review. JAMA Surg 2017; 152: 1066-1071.
- [60] ünülü M and Kaya N. The effect of neiguan point (p6) acupressure with wristband on postoperative nausea, vomiting, and comfort level: a randomized controlled study. J Perianesth Nurs 2018; 33: 915-927.

Supplementary Table 1. The search strategy in this review

A. Searc	h strategy for PubMed (84)
Search	Terms
#1	 ((((((((((((((((((((((((((((((((((((
#2	((((((((((((((((((((((((((((((((((((((
#3	((randomized controlled trial[Publication Type]) OR (randomized[Title/Abstract])) OR (placebo[Title/ Abstract])
#4	#1 AND #2 AND #3
B. Searc	h strategy for Embase (83)
Search	Terms
#1	'Knee arthroplasty'/exp
#2	'arthroplasty, replacement, knee' OR 'arthroplasties, replacement, knee' OR 'arthroplasty, knee replacement' OR 'knee replacement arthroplasties' OR 'knee replacement arthroplasty' OR 'replace- ment arthroplasties, knee' OR 'knee arthroplasty, total' OR 'arthroplasty, total knee' OR 'total knee arthroplasty' OR 'replacement, total knee' OR 'total knee replacement' OR 'knee replacement, total' OR 'knee arthroplasty' OR 'arthroplasty, knee' OR 'arthroplasties, knee replacement' OR 'replacement arthroplasty, knee' OR 'arthroplasty, replacement, partial knee' OR 'unicompartmental knee arthro- plasty'
#3	'arthroplasty, unicompartmental knee' OR 'knee arthroplasty, unicompartmental' OR 'unicondylar knee arthroplasty' OR 'arthroplasty, unicondylar knee' OR 'knee arthroplasty, unicondylar' OR 'partial knee arthroplasty' OR 'arthroplasty, partial knee' OR 'knee arthroplasty, partial' OR 'unicondylar knee re- placement' OR 'knee replacement, unicondylar' OR 'partial knee replacement' OR 'knee replacement, partial' OR 'unicompartmental knee replacement' OR 'knee replacement, unicompartmental'
#4	#1 OR #2 OR #3
#5	'electrostimulation'/exp
#6	'transcutaneous electrical acupoint stimulation' OR 'transcutaneous acupoint electrical stimulation' OR teas OR taes OR acustimulation OR 'transcutaneous electrical nerve stimulation' OR acupoints
#7	#5 OR #6
#8	'clinical trial'/exp OR 'clinical trial' OR (('clinical' OR 'clinical'/exp OR clinical) AND ('trial' OR 'trial'/exp OR trial)) OR (randomized AND controlled AND ('trial'/exp OR trial)) OR trials
#8	#4 AND #7 AND #8
C. Searc	h strategy for CENTRAL (41)
Search	Terms
#1	(transcutaneous electrical acupoint stimulation):ti,ab,kw
#2	(transcutaneous acupoint electrical stimulation):ti,ab,kw
#3	(TEAS):ti,ab,kw
#4	(TAES):ti,ab,kw
#5	(acustimulation) ti ab kw

#5 (acustimulation):ti,ab,kw

- #6 (Transcutaneous electrical nerve stimulation on acupoints):ti,ab,kw
- #7 MeSH descriptor: [Electric Stimulation] explode all trees
- #8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
- #9 MeSH descriptor: [Arthroplasty, Replacement, Knee] explode all trees
- #10 ((Arthroplasty, Replacement, Knee) OR (Arthroplasties, Replacement, Knee) OR (Arthroplasty, Knee Replacement) OR (Knee Replacement Arthroplasties) OR (Knee Replacement Arthroplasty) OR (Replacement Arthroplasties, Knee) OR (Knee Arthroplasty, Total) OR (Arthroplasty, Total Knee) OR (Total Knee Arthroplasty) OR (Replacement, Total Knee) OR (Total Knee Replacement) OR (Knee Replacement, Total) OR (Knee Arthroplasty) OR (Arthroplasty, Knee) OR (Arthroplasties, Knee Replacement) OR (Replacement Arthroplasty, Knee) OR (Arthroplasty, Replacement, Partial Knee) OR (Unicompartmental Knee Arthroplasty) OR (Arthroplasty, Unicompartmental Knee) OR (Knee Arthroplasty, Unicompartmental) OR (Unicondylar Knee Arthroplasty) OR (Arthroplasty, Unicondylar Knee) OR (Knee Arthroplasty, Unicondylar) OR (Partial Knee Arthroplasty) OR (Arthroplasty, Partial Knee) OR (Knee Arthroplasty, Partial) OR (Unicondylar Knee Replacement) OR (Knee Replacement, Unicondylar) OR (Partial Knee Replacement) OR (Knee Replacement) OR (Knee Replacement, Unicondylar) OR (Partial Knee Replacement) OR (Knee Replacement, Partial) OR (Unicompartmental Knee Replacement) OR (Knee Replacement) OR (Knee Replacement, Partial) OR (Unicompartmental Knee Replacement) OR (Knee Replacement, Unicompartmental)):ti,ab,kw
- #11 #9 OR #10

#12 #8 AND #11

D. Search strategy for CNKI (74)

(SU% = transcutaneous acupoint electrical stimulation + acupoint electrical stimulation + electrical stimulation) AND (SU % = knee replacement + joint replacement + total knee replacement)

E. Search strategy for WanFang (77)

Topic: ('transcutaneous electrical acupoint stimulation' OR 'acupoint electrical stimulation' OR 'electrical stimulation') and Topic: ('knee replacement' OR 'joint replacement' OR 'total knee replacement')

F. Search strategy for VIP (79)

(U = transcutaneous acupoint electrical stimulation OR acupoint electrical stimulation OR electrical stimulation) AND (U = knee replacement OR joint replacement OR total knee replacement)

G. Search strategy for CBM (88)

('Knee replacement' [all fields: intelligent] OR 'joint replacement' [all fields: intelligent] OR 'total knee replacement' [all fields: intelligent]) AND ('transcutaneous electrical acupoint stimulation' [all fields: intelligent] OR 'acupoint electrical stimulation' [all fields: intelligent] OR 'electrical stimulation' [all fields: intelligent])

Dutcomes	References	Effect size	95% CI	Р	²
/AS	Hu 2021	-0.58	-0.71, -0.45	< 0.00001	82%
	Tong 2020	-0.61	-0.75, -0.47	< 0.00001	85%
	Wang(a) 2021	-0.61	-0.75, -0.47	< 0.00001	85%
	Wang 2022	-0.59	-0.72, -0.45	< 0.00001	84%
	Zhang(a) 2019	-0.60	-0.75, -0.46	< 0.00001	85%
	Bai 2018	-0.59	-0.73, -0.46	< 0.00001	84%
	Tong 2020	-0.61	-0.75, -0.47	< 0.00001	85%
	Wang(a) 2021	-0.61	-0.74, -0.47	< 0.00001	85%
	Zhang 2021	-0.59	-0.72, -0.45	< 0.00001	84%
	Bai 2018	-0.59	-0.73, -0.46	< 0.00001	84%
	Bai 2023	-0.60	-0.74, -0.46	< 0.00001	85%
	Chen 2019	-0.60	-0.74, -0.46	< 0.00001	85%
	Hu 2021	-0.61	-0.75, -0.48	< 0.00001	84%
	Tong 2020	-0.62	-0.75, -0.48	< 0.00001	84%
	Wang(a) 2021	-0.61	-0.75, -0.48	< 0.00001	84%
	Wang(b) 2021	-0.61	-0.75, -0.47	< 0.00001	85%
	Wang 2022	-0.60	-0.73, -0.46	< 0.00001	85%
	Xie 2021	-0.60	-0.74, -0.46	< 0.00001	85%
	Zhang(a) 2019	-0.62	-0.75, -0.48	< 0.00001	84%
	Zhang(b) 2019	-0.63	-0.76, -0.49	< 0.00001	84%
	Zhang 2021	-0.59	-0.73, -0.45	< 0.00001	84%
	Zhuang 2019	-0.62	-0.75, -0.48	< 0.00001	84%
	Bai 2018	-0.58	-0.72, -0.45	< 0.00001	84%
	Chen 2019	-0.61	-0.74, -0.47	< 0.00001	85%
	Cui 2021	-0.61	-0.75, -0.47	< 0.00001	85%
	Hu 2021	-0.61	-0.75, -0.47	< 0.00001	85%
	Li 2021	-0.60	-0.73, -0.46	< 0.00001	85%
	Tong 2020	-0.61	-0.75, -0.48	< 0.00001	84%
	Wang(a) 2021	-0.60	-0.74, -0.46	< 0.00001	85%
	Wang(b) 2021	-0.60	-0.74, -0.46	< 0.00001	85%
	Xie 2021	-0.61	-0.75, -0.47	< 0.00001	85%
	Zhang(a) 2019	-0.62	-0.75, -0.48	< 0.00001	84%
	Zhang 2021	-0.60	-0.74, -0.46	< 0.00001	84%
	Bai 2018	-0.59	-0.73, -0.46	< 0.00001	84%
	Bai 2023	-0.60	-0.74, -0.46	< 0.00001	85%
	Chen 2019	-0.60	-0.74, -0.46	< 0.00001	85%
	Cui 2021	-0.60	-0.74, -0.46	< 0.00001	85%
	Li 2021	-0.60	-0.73, -0.46	< 0.00001	85%
	Wang(b) 2021	-0.60	-0.74, -0.46	< 0.00001	85%
	Xie 2021	-0.61	-0.75, -0.47	< 0.00001	85%
	Zhuang 2019	-0.57	-0.70, -0.44	< 0.00001	81%
	Bai 2023	-0.61	-0.75, -0.47	< 0.00001	85%
	Chen 2019	-0.60	-0.74, -0.46	< 0.00001	85%
	Cui 2021	-0.60	-0.74, -0.46	< 0.00001	85%
	Li 2021	-0.62	-0.75, -0.48	< 0.00001	83% 84%
	Wang(b) 2021	-0.62	-0.75, -0.48	< 0.00001	84%
	- · ·				
	Xie 2021	-0.62	-0.76, -0.48	< 0.00001	84% 85%
	Zhuang 2019	-0.61	-0.75, -0.47	< 0.00001	85%
	Kim 2021	-0.60	-0.74, -0.47	< 0.00001	85%

Supplementary Table 2. Sensitivity analysis for VAS, functional scores

Function	Bai 2023	5.08	2.67, 7.49	< 0.0001	91%
	Li 2019	4.04	2.05, 6.03	< 0.0001	89%
	Li 2021	4.60	2.36, 6.84	< 0.0001	90%
	Liang 2017	5.01	2.67, 7.35	< 0.0001	91%
	Liang 2017	5.09	2.72, 7.46	< 0.0001	91%
	Wu 2017	4.20	2.26, 6.14	< 0.0001	85%
	Xie 2021	4.60	2.39, 6.81	< 0.0001	91%
	Zhang 2021	5.30	3.39, 7.21	< 0.00001	79%
	Zhuang 2019	5.09	2.50, 7.69	= 0.0001	91%



Supplementary Figure 1. Funnel plot analysis. A. Funnel plot analysis of VAS. B. Funnel plot analysis of functional score.

Outcomes	Ν	Begg's test	Egger's test	
Postoperative pain (6 h)	5	0.806	0.816	
Postoperative pain (12 h)	4	1	0.961	
Postoperative pain (24 h)	13	0.760	0.815	
Postoperative pain (48 h)	11	0.276	0.291	
Postoperative pain (72 h)	8	0.174	0.989	
Postoperative pain (7 d)	7	0.548	0.053	
Postoperative pain (14 d)	2	1	NA	
Function (HSS)	6	0.452	0.074	
Function (KSS)	3	0.296	0.241	
ROM	6	0.452	0.998	
Analgesia-Related Adverse Effects	12	0.244	0.3	
CRP	3	1	0.943	
IL-6	4	0.734	0.180	

Supplementary Table 3. Assessment of publication bias

N: number of studies; NA: not available.

TEAS for rehabilitation after TKA

Patient or population: patients with rehabilitation after TKA

Settings: ٩S

Int	ter	٧e	n	tio	n:	IEA

Outcomes	Illustrative co	mparative risks* (95% CI)	Relative effect	No of Participants	Quality of the evidence	Comments
	Assumed risk	Corresponding risk	(95% CI)	(studies)	(GRADE)	
	Control	TEAS				
VAS - Pain (6h)		The mean vas - pain (6h) in the intervention groups was		334	0 000	
		0.86 lower		(5 studies)	very low ¹	
		(1.35 to 0.37 lower)				
VAS - Pain (12h)		The mean vas - pain (12h) in the intervention groups was		213	0000 B	
		0.86 lower		(4 studies)	low ¹	
		(1.37 to 0.36 lower)				
VAS - Pain (24h)		The mean vas - pain (24h) in the intervention groups was		895	0000	
		0.39 lower		(13 studies)	low ¹	
		(0.6 to 0.17 lower)				
VAS - Pain (48h)		The mean vas - pain (48h) in the intervention groups was		667	000 j	
		0.47 lower		(11 studies)	very low ¹	
		(0.77 to 0.17 lower)				
VAS - Pain (72h)		The mean vas - pain (72h) in the intervention groups was		514	0000 0 00	
		0.95 lower		(8 studies)	low ¹	
		(1.36 to 0.54 lower)				
VAS - Pain (7d)		The mean vas - pain (7d) in the intervention groups was		474	0000	
		0.56 lower		(7 studies)	low ¹	
		(0.86 to 0.26 lower)				
VAS - Pain (14d)		The mean vas - pain (14d) in the intervention groups was		112	0000	
		0.5 lower		(2 studies)	moderate ¹	
		(0.76 to 0.24 lower)				

The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval;

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate

Very low quality: We are very uncertain about the estimate.

¹ No explanation was provided

TEAS for rehabilitation after TKA

Patient or population: patients with rehabilitation after TKA

Settings: Intervention: TEAS

Outcomes	Illustrative con Assumed risk Control	nparative risks* (95% CI) Corresponding risk TEAS	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
HSS		The mean hss in the intervention groups was 3.96 higher (1.6 to 6.32 higher)		507 (6 studies)	⊕⊕⊝⊝ low ¹	
KSS		The mean kss in the intervention groups was 7.33 higher (1.22 to 13.45 higher)		212 (3 studies)	⊕⊖⊖⊖ very low ¹	

The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval:

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate

Very low quality: We are very uncertain about the estimate.

¹ No explanation was provided

TEAS for rehabilitation after TKA

Patient or population: patients with rehabilitation after TKA

Settings:

In	ten	/ent	ion:	TEAS

Outcomes	Illustrative com Assumed risk Control	oparative risks* (95% CI) Corresponding risk TEAS	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
Rom		The mean rom in the intervention groups was 5.61 higher (4.08 to 7.14 higher)		329 (6 studies)	⊕⊕⊝⊝ low ¹	

The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval;

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹ No explanation was provided

Patient or population: patients with rebailiable after TrGs Settings: Intervention: TLG3 Determine Assumd ray, Comments Assumd ray, Corresponding ray, Control TEAS Control Settings: Control Setting: Control Setti	TEAS for rehabilitation after TKA							
Assume rate Corresponding risk 1995 (C) Installer() CRIAIL() Haus set Yomiting Stady population Corresponding risk 0 (C 2 10 6.45) 7/4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Settings:							
Hease eV rowing Easing population (C + D + S), (C +	Outcomes	Ass	sumed risk	Corresponding risk				ence Comments
C2 to 0.45 (12 studies) moderate (24 to 0.45 (12 studies) moderate (12 studies) (12 studies) (12 studies) (12 studies) (12 studies) moderate (12 studies)	Nausea/Vomiti			1043	OR 0.3	744	@@@ 0	
Moderate Moderate Moderate The basis for the assumed ratk (e.g. the median control group fix across a tubes) is provided in footnotes. The corresponding risk (and ta 55% confidence interval) is based on the assumed risk (e.g. the median control group fix across a tubes) is provided in footnotes. The corresponding risk (and ta 55% confidence interval) is based on the assumed risk (e.g. the median control group fix across a tubes) is provided in footnotes. The corresponding risk (and ta 55% confidence interval) is based on the assumed risk (e.g. the median control fixed in the estimate of effect and is likely to change the estimate. CAPLE for rehabilitation after TKA Patient or oppulation: patients with rehabilitation after TKA. CAPP The means cip in the intervention groups was (control GRD group fixed control GRD group) (15% CO) Relative effect and is likely to change the estimate. Comments CAPP The means cip in the intervention groups was (control GRD group) (15% CO) Relative effect and may change the estimate. Comments CAPP The means cip in the intervention groups was (control GRD group) (15% CO) Relative effect and may change the estimate. Comments CAPP The assumed rak (c.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and to 55% confidence interval) is based on the assumed rak (c.g. the median control group risk across studies) is provided in footnotes. Comments CAP	nuuseu voinia	-						
Date per 1000 114 per 1000 "The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison and the relative effect of the intervention (and its 95% C.). CEC confidence interval, OEC 0056 ratio: Confidence interval, OEC 0056 ratio: ORDORE "Fulficience interval, OEC 0056 ratio: Confidence interval, OEC 0056 ratio: Ceconfidence interval, OEC 0056 ratio: Confidence interval, OEC 0056 ratio: Ceconfidence interval, OEC 0056 ratio: Confidence interval, OEC 0056 ratio: Ceconfidence interval, OEC 0056 ratio: Confidence interval, OEC 0056 ratio: Ceconfidence interval, OEC 0056 ratio: Confidence interval, OEC 0056 ratio: Ceconfidence interval, OEC 0056 ratio: Confidence interval, OEC 0056 ratio: Ceconfidence interval, OEC 0056 ratio: Confidence interval, OEC 0056 ratio: Ceconfidence interval, OEC 0056 ratio: Confidence interval, OEC 0056 ratio: Ceconfidence interval, OEC 0056 ratio: Confidence interval, OEC 0056 ratio: Ceconfidence interval, OEC 0056 ratio: Confidence interval, OEC 0056 ratio: Ceconfidence interval, OEC 0056 ratio: Confidence interval, OEC 0056 ratio: Ceconfidence interval, OEC 0056 ratio: Confidence interva		Mo	derate	(
rakis the comparison group and the relative effect of the intervention (and its 95% C). Ch Confidence intervat, OR: Odds ratio: CC P and the strate of our confidence in the estimate of effect and may change the estimate. Very low quality: further research is skely to have an important mode of our confidence in the estimate of effect and is likely to change the estimate. Very low quality: further research is skely to have an important mode of our confidence in the estimate of effect and is likely to change the estimate. Very low quality: further research is skely to have an important mode of our confidence in the estimate of effect and is likely to change the estimate. Very low quality: further research is skely to have an important mode of our confidence in the estimate of effect and is likely to change the estimate. Very low quality: further research is skely to have an important mode of effect. Relative effect is comparative risker (95% CI) Assumed file: Consequencing (19% CI) Ass		300	per 1000					
GAAE Vicking Group grades of evidence High quality, Further research is will while by the ware microfild model on our confidence in the estimate of effect and may change the estimate. Moderate quality: Further research is will be by the magnetiant model on our confidence in the estimate of effect and may change the estimate. Very water research is will be by the magnetiant model on our confidence in the estimate of effect and may change the estimate. Very water research is will be been model in the estimate of effect and may change the estimate. Very water research is will be estimate of effect. No of Participants Control CRP Control CRP The mean cry in the intervention groups was Control CRP The mean cry in the intervention groups was Control CRP The head cry water research is will be participant is will be estimate. Control CRP The mean cry in the intervention groups was Control CRP The head cry water research is will be participant is worked in footnotes. The corresponding risk (and ts 55% confidence interval) is based on the assumed risk is the comparison group and the relative effect of the intervention (and as 55% C). CL Confidence interval; CARD Werking Group grades of evidence High quality. Further research is will be assumed in the estimate of effect. High quality. Further research is will be assumed in the estimate of effect. High quality. Further research is will be assumed in the estimate of effect. High quality. Further research is will be assumed in the estimate of effect. High quality. Further research is will be assumed in the estimate of effect. High quality. Further research is will be assumed in the estimate of effect. High quality. Fu						tes. The corresponding	g risk (and its 95% confidence i	nterval) is based on the assumed
High quality Futher research is you unkey to change our confidence in the estimate of effect and may change the estimate. Low quality: Futher research is well well on an end of the estimate of effect and may change the estimate. Low quality: Futher research is well well on an end of the estimate of effect and may change the estimate. Teleform to population: patient about the estimate of effect. The research is likely to the population of the estimate of effect. The teleform to population: patient about the estimate of effect. The teleform to population: patient about the estimate of effect. The teleform to population: patient about the estimate of effect. The teleform to population: patient about the estimate of effect and may change the estimate. Teleform to population: patient about the estimate of effect. The teleform t	CI: Confidence i	interval; OR: Odds	ratio;					
CRP for rehabilitation after TKA Patient or population: patients with rehabilitation after TKA Settings: Intervention: CRP Outcomest Control Illustrative comparative risks* (95% CI) Assumed risk Relative effect (55% CI) No of Participants (studies) Quality of the evidence (CRADE) Comments (CRADE) Outcomest Control CRP The mean crp in the intervention groups was (157 to 0.22 kwer) 170 (3 studies) Quality of the evidence (157 to 0.22 kwer) SMD - 0.92 (-1.57 to -0.27) The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and ts 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and \$8 95% CI). CC Confidence interval) CC Confidence interval) Stades CADE Working Group grades of evidence High quality: Futher research is very unkely to change our confidence in the estimate of effect. Hoodrage studies: High quality: Futher research is very unkely to change our confidence in the estimate of effect and may change the estimate. Very low quality: We are very uncertain about the estimate Confidence interval) Relative effect the stimute of the stimute. Very low quality: We are very uncertain about the estimate. Control Comments (Studies) Comments (Studies) Test for rehabilitation after TKA Falsen or population: patient or population: patient or population: patient or population: patie	High quality: Fi Moderate qual Low quality: Fi	urther research is lity: Further resear urther research is	very unlikely to cha ch is likely to have very likely to have	an important impact on our confide an important impact on our confide	ence in the estimate	of effect and may chang of effect and is likely to c	ge the estimate. change the estimate.	
Patient or population: patients with rehabilitation after TKA. Setting: Intervention: CRP Quality of the evidence (GRADC) Comments (GRADC) Dateomes Blastrative comparative risks* (95% CI) Assumed risk. Relative effect (95% CI) No of Participants (95% CI) Quality of the evidence (GRADC) Comments CRP The mean cry in the intervention groups was (15% CI) (15% CI) (15% CI) Guides) SMD -0.92 (-1.57 to -0.27) The basis for the assumed risk (e.g. the media control group risk across studies) is provided in footnotes. The corresponding risk (and ts 95% confidence interval) is based on the assumed risk is the comparison group and the relative effect of the intervention (and ts 95% CI). Edited of the confidence interval. CRADE Working Group grades of evidence task is the comparison group and the relative effect of the intervention (and ts 95% CI). Editation of evidence task is the comparison group and the relative of the stimate of effect. CRADE Working Group grades of evidence task is the comparison group used the stimate of or floct. Hour on the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. Very low quality: We are very uncertain about the estimate. Very way quality: We are very uncertain about the estimate. (15% CI) Relative effect 1 No of Participants (GRADE) Quality of the evidence (GRADE) SMD -1.29 (-2.07 to -0.51) (-4 studie	¹ No explanation	n was provided						
Settings: Intervention: CRP Dutcomes Illustrative comparative risks* (95% CI) Assumed risk Corresponding risk Control CRP Control CRP Control CRP	CRP for rehat	bilitation after Th	(A					
Assumed risk Control CGRP (GRADE) CRP The mean crp in the binstruention groups was 0.52 standard deviations lower (1.57 to 0.27 lower) 170 (3 studies) ⊕⊕⊖⊖ tow ³ SMD -0.92 (-1.57 to -0.27) (0 studies) **The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CEC CEC confidence interval; CRADE Working Group grades of evidence High quality: Futher research is levely to change our confidence in the estimate of effect and may change the estimate. Low quality: Futher research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Low quality: Futher research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Low quality: We are very uncertain about the estimate. Very low quality: We are very uncertain about the estimate. Fefect and may change the estimate. Low quality: Futher research is likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Low quality: We are very uncertain about the estimate. Cemments Text Stor rehabilitation after TKA Settings: Intervention: TEAS Felative effect (SC CI) Research is likely to have an important impact on our confidence intervention (roups was (20 rto 0.51 lower) SMD -1.29 (-2.07 to -0.51) (-2.07 to 0.51 lower) The basis for the assumed risk (e.g. th	Settings:		with rehabilitation a	fter TKA				
Control CRP The mean crp in the intervention groups was 0.22 standard deviations lower (1.57 to 0.27 kower) SMD -0.92 (-1.57 to -0.27) (0.07 to 0.27 kower) ************************************	Outcomes							Comments
0.92 standard deviations lower (3 studies) low ¹ Intervention of the control of				sk	(95% CI)	(studies)	(GRADE)	
risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; GRADE Working Group grades of evidence High quality: Further research is very luck) to have an important impact on our confidence in the estimate of effect and may change the estimate. Very low quality: Further research is very luck) to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: Further research is very luck) to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. ¹ No explanation was provided TEAS for rehabilitation after TKA Patient or population: patients with rehabilitation after TKA Settings: Intervention: TEAS Duicomes Illustrative comparative risks* (95% CI) Assumed risk Corresponding risk Control TEAS IL-6 The mean i-6 in the intervention group was 1.29 standard deviations lower (2.07 to 0.51 lower) ¹ The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% cOI) Ci: Confidence interval; GRADE Working Group grades of evidence High quality: Further research is very likely to change our confidence in the estimate of effect. Moderate quality: Further research is very unikely to change our confidence in the estimate of effect. Moderate quality: Further research is key to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very unikely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Low quality: Further research is very unikely to have an important impact on our confidence in the estimate of effect and i	CRP		0.92 standard d	leviations lower				SMD -0.92 (-1.57 to -0.27)
Moderate quality: Further research is key to have an important impact on our confidence in the estimate of effect and may change the estimate. ¹ No explanation was provided TEAS for rehabilitation after TKA Patient or population: patients with rehabilitation after TKA Settings: Intervention: TEAS Outcomest Illustrative comparative risks* (95% CI) Assumed risk Corresponding risk Control TEAS Relative effect (95% CI) (5% CI) (4 studies) [0% III (4 studies) [0% IIII (4 studies) [0% IIII (4 studies) [0% IIII (4 studies) [0% IIIIIII [0% IIIIIIII (4 studies) [0% IIII	risk in the comparison group and the relative effect of the intervention (and its 95% Cl). CI: Confidence intervat; GRADE Working Group grades of evidence							
¹ No explanation was provided TEAS for rehabilitation after TKA Patient or population: patients with rehabilitation after TKA. Settings: Intervention: TEAS Outcomes Illustrative comparative risks* (95% CI) Assumed risk Control Relative effect (95% CI) No of Participants (studies) Quality of the evidence (GRADE) Comments IL-6 The mean II-6 in the intervention groups was 1.29 standard deviations lower (2.07 to 0.51 lower) 254 (4 studies) @@@@@ SMD -1.29 (-2.07 to -0.51) *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; GRADE Vorking Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very unlikely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is about the estimate. Very low quality: We are very uncertain about the estimate.	Moderate qual Low quality: Fu	lity: Further resear urther research is	ch is likely to have very likely to have	an important impact on our confide an important impact on our confide	ence in the estimate			
Patient or population: patients with rehabilitation after TKA Settings: Intervention: TEAS Outcomes Illu strative comparative risks* (95% CI) Assumed risk Control Relative effect (95% CI) No of Participants (studies) Quality of the evidence (GRADE) Comments IL-6 The mean i-6 in the intervention groups was 1.29 standard deviations lower (2.07 to 0.51 bwer) 254 (4 studies) Quality of the evidence (GRADE) Comments *The basis for the assumed risk (e.gthe median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). SMD -1.29 (-2.07 to -0.51) (velocity) Cl: Confidence interval; GRADE Smother across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group grades of evidence High quality: Further research is very unikely to change our confidence in the estimate of effect. Moderate quality: Further research is key to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: We are very uncertain about the estimate. Very low quality: We are very uncertain about the estimate. Very low quality: We are very uncertain about the estimate.								
Patient or population: patients with rehabilitation after TKA Settings: Intervention: TEAS Outcomes Illu strative comparative risks* (95% CI) Assumed risk Control Relative effect (95% CI) No of Participants (studies) Quality of the evidence (GRADE) Comments IL-6 The mean i-6 in the intervention groups was 1.29 standard deviations lower (2.07 to 0.51 bwer) 254 (4 studies) Quality of the evidence (GRADE) Comments *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). SMD -1.29 (-2.07 to -0.51) (4 studies) Cl: Confidence interval; GRADE SMD -1.29 (-2.07 to -0.51) Cl: Confidence interval; GRADE SMD -1.29 (-2.07 to -0.51) Using Group grades of evidence High quality; Further research is very unikely to change our confidence in the estimate of effect. Moderate quality: Further research is key to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: We are very uncertain about the estimate. Very low quality: We are very uncertain about the estimate.	TEAS for roba	bilitation after T	164					
Assumed risk Control Corresponding risk TEAS (95% CI) (studies) (GRADE) IL-6 The mean II-6 in the intervention groups was (2 07 to 0.51 lower) 254 (4 studies) 000 ¹ SMD -1.29 (-2.07 to -0.51) low ¹ **The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and 8s 95% CI). CL CL Cl Confidence interval; GRADE Working Group grades of evidence High quality; Further research is very linkely to change our confidence in the estimate of effect. Moderate quality: Further research is key to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: We are very uncertain about the estimate. Very low quality; We are very uncertain about the estimate.	Patient or population: patients with rehabilitation after TKA Settings:							
IL-6 The mean II-6 in the intervention groups was 1.29 standard deviations lower (2.07 to 0.51 lower) 254 ⊕⊕⊝⊝ SMD -1.29 (-2.07 to -0.51) *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% Cl). Cl: Confidence interval; GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Hode stimate. Moderate quality: Further research is very unlikely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is about the estimate. Very low quality: We are very uncertain about the estimate.	Outcomes	Assumed risk	Corresponding ris					Comments
risk in the comparison group and the relative effect of the intervention (and its 95% Cl). Cl: Confidence interval; GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is kiely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very uncertain about the estimate on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.	IL-6		1.29 standard d	leviations lower				SMD -1.29 (-2.07 to -0.51)
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.	risk in the comparison group and the relative effect of the intervention (and its 95% CI).							
¹ No explanation was provided	GRADE Working High quality: Fu Moderate qual Low quality: Fu Very low quali	Group grades of urther research is lity: Further resear urther research is ity: We are very ur	very unlikely to cha ch is likely to have very likely to have	an important impact on our confide an important impact on our confide	ence in the estimate			
	¹ No explanation	was provided						

Supplementary Figure 2. Evidence quality assessment.